PD1 Non-Small Cell Lung Cancer Treatment Market

PD1 Non-Small Cell Lung Cancer Treatment Market Snapshot (2023 to 2033)

The global PD1 non-small cell lung cancer treatment market size is expected to surpass an impressive valuation of USD 26.96 Billion in 2023 and is projected to reach USD 61 Billion by 2033, growing at a CAGR of 8.51%

The presence of a strong pipeline for NSCLC is projected to propel growth over the coming years. For instance, fruquintinib (HMPL-013), a drug developed to treat advanced non-small cell lung cancer is in the clinical trial phase. Furthermore, Avelumab developed by Merck KGaA is currently in the pipeline. It is a fully human monoclonal PD-L1 antibody. Thus, the development of such advanced treatments is expected to drive the market during the forecast period.

High growth is attributed to the growing patient population, expected entry of several drugs, and increasing investment by industry players in the Research and Development (R&D) of NSCLC therapy. The increasing prevalence of NSCLC across the globe owing to increasing air pollution and smoking habits amongst people is likely to propel market growth over the coming years.

Report Attribute	Details
Expected Market Value (2023)	USD 26.96 Billion
Anticipated Forecast Value (2033)	USD 61 Billion
Projected Growth Rate (2023 to 2033)	CAGR 8.51%

2018 to 2022 PD1 Non-Small Cell Lung Cancer Treatment Demand Analysis vs. Forecast 2023 to 2033

The market revenue for PD1 Nonsmall cell lung cancer treatment was USD 18.2 Billion in 2018 while exhibiting a CAGR of 5.7%. Pharmaceutical companies have begun to develop additional anti-PD-1/PD-L1 antibodies to overcome resistance and are devising further immunotherapy combinations which is creating space for market expansion.

More than 20 anti-PD-1/PD-L1 antibodies have been approved or are currently in development. Numerous combination therapies are under development, and several combination therapies have provided positive results in randomized controlled trials which presents growth avenues for the market.

The global increase in cancer cases boosts the global non-small cell lung cancer market during the forecast period. According to American Cancer Society statistics from 2020, the majority of cases of SCLC occur in people between the ages of 60 and 80, with a global death rate of 30,000 per year.

Furthermore, according to WHO data, lung cancer is the second most common cancer in men and women, accounting for around 3 million deaths in 2020. This boosts the market growth. Thus, considering these factors and developments, FMI has estimated the market to gross a value of USD 61 Billion with a CAGR of 8.51% by end of the forecast period.

Which are Some Prominent Drivers of the PD1 Non-small cell lung cancer treatment market?

New drug approvals to fuel market growth

The rising number of new drug approvals by regulatory authorities for the treatment of non-small cell lung cancer is anticipated to drive the growth of the market. For instance, in May 2019, Pfizer Inc., which is a USA-based multinational pharmaceutical and biotechnology corporation received the European Commission’s (EC) marketing authorization for the LORVIQUA drug, a monotherapy drug used for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). This development will aid in market growth.

Moreover, with the approval of Nivolumab, immune-checkpoint inhibitors (ICIs), mainly anti-programmed cell death-1 (PD-1) antibodies, have rapidly revolutionized cancer treatment which is anticipated to drive the market in the forecast period. The recommendation of combination therapy with an anti-PD-1/PD-L1 antibody and platinum-based chemotherapy as a first-line therapy for patients with advanced NSCLC without driver gene mutations will augment the growth of the PD1 Non-small cell lung cancer treatment market during the forecast period

Rising demand for oral drugs to augment product demand

Oral drugs are expected to boost the market growth. The segment is estimated to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

What are the Challenges Projected to be Faced by the Market?

Lack of skilled professionals restraining market growth

The dearth of trained professionals who are unaware of treatment methods for this disease may restrict the growth of the global PD1 non-small cell lung cancer treatment market during the forecast period.

High cost of treatment to hamper market expansion

The high cost of drugs is a major blockade for patients to adopt these drugs easily. Thus, presenting challenges for market expansion.

Region-Wise Insights

What is the growth outlook in North America?

North America rules the market with the highest market share

This region is expected to dominate the market with a market share of 42% during the forecast period. The market in the USA was estimated at USD 9.2 Billion in 2022. The growth is attributed due to increasing support from the USA Government for developing therapies and drugs to treat different types of cancer. The availability of state-of-the-art research facilities and access to advanced testing equipment helps with successful research, which is contributing to market growth.

Furthermore, high research and development activities, the launch of companion diagnostics by industry players, and massive healthcare spending are propelling the growth of the overall regional market to a large extent. ?The cost of treatment which includes chemotherapy, immunotherapy, targeted therapy, radiation, and in some cases, surgery, is vast, and the availability of significant reimbursement in the region is likely to augment market growth.

What are the growth prospects in South Asia?

South Asia to witness the fastest growth in the forecast period

This region is expected to witness the fastest CAGR of 8% in the forecast period. The market in this region is projected to account for 25.5% of revenue by 2033. China is expected to grow at a CAGR of 13.7% with a market valuation to reach USD 12.2 Billion by end of the forecast period. The growth in this region is attributable to the presence of a large patient population and the rise in research and development activities in the pharmaceutical sector.

Moreover, the presence of companies and growth in the purchasing power of countries like India and China will fuel product demand. Also, the rise in the adoption of therapies for cancer and the adoption of high-tech processing to improve training programs are driving growth in this region.

Category wise Insights

By Treatment Type, which segment is most likely to dominate the market?

Demand for Targeted Cancer Therapies on the Rise

Targeted therapy is expected to dominate the market by reaching a valuation of USD 31.7 Billion by end of the forecast period while exhibiting a CAGR of 10%. This segment is expected to continue this trend owing to distinct clinical benefits offered by this therapy such as minimal side effects along with the availability of a number of targeted therapeutics.

In addition, rise in the number of people turning to targeted therapy as a form of treatment for cancer, and targeted therapy is successful in up to 80% of cases. These factors will propel the segment’s growth in the upcoming years.

By Distribution Channel, which segment will possess the highest market share?

Hospital Pharmacies account for the Maximum Availability of key Drugs

This segment is expected to account for 52% market share while trailing at a CAGR of 12% during the forecast period. The dominance is due to an increase in the number of hospitalizations of patients suffering from PD1 Non-small cell lung cancer and the presence of skilled professionals within these settings.

Start-ups in PD1 Non-small cell lung cancer treatment market

• Founded in 2016, ‘Ikena Oncology’ is a USA-based start-up that develops biomarker-based therapies for treating cancer. The lead product candidate IK-007 is currently in clinical development for the treatment of microsatellite stable colorectal cancer and PD-1/L1 refractory non-small cell lung cancer. The other drug candidates include IK-930 for Hippo-mutated cancers and solid tumors, IK-1751 for bladder cancer, and others. It received a total funding of USD 168 million from Omega Funds, Fidelity Investments, and 10 others.
• Founded in 2012, ‘Junshi’ Biopharma is a shanghai-based company that provides antibody-based therapeutics for multiple diseases. The company's drug candidates include anti-PD-1 monoclonal antibodies, PCSK9 monoclonal antibodies, anti-BLyS monoclonal antibodies, and others for the treatment of cancer, metabolic, neurology, immunology, and infectious diseases.

Market Competition

The market is fragmented and moderately competitive. The strategies like mergers and acquisitions adopted by major market players will boost the market growth. The major players in the market are Merck Co. & Inc, Bristol-Myers Squibb, F. Hoffmann-La Roche AG, AstraZeneca Plc, Pfizer Inc, Merck KGaA, Novartis AG, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Sanofi, and Agennix AG. Some recent developments in this industry are:

• In January 2021, The Lung Ambition Alliance, which is a global coalition with the bold ambition to eliminate lung cancer as a cause of death, started The Initiatives in Lung Cancer Care (ILC2) program. The aim of the program is to fund projects that drive measurable improvements across the patient journey, from early detection to palliative care or survivorship.
• In August 2022, the Food and Drug Administration granted regular approval to capmatinib (Tabrecta, Novartis Pharmaceuticals Corp.) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.
• In March 2022, Regeneron and BioNTech expanded their collaboration agreement for the development of Libtayo and FixVac (cemiplimab) Combination to treat advanced NSCLC.
• In 2021, Daiichi Sankyo received FDA approval for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma.

Report Scope

Report Attribute	Details
Market Value in 2023	USD 26.96 Billion
Market Value in 2033	USD 61 Billion
Growth Rate	CAGR of 8.51% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	treatment, drug type, cancer type, distribution channel, region
Regions Covered	north america; latin america; europe;  south asia; east asia; oceania; middle east & africa
Key Countries Profiled	the usa, canada, brazil, mexico, germany, the united kingdom, france, spain, italy, india, malaysia, singapore, thailand, china, japan, south korea, australia, new zealand, gcc countries, south africa, israel
Key Companies Profiled	merck co. & inc.; bristol-myers squibb; f. hoffmann-la roche ag; astrazeneca plc.; pfizer inc.; novartis ag; glaxosmithkline plc.; takeda pharmaceutical company limited; eli lilly and company; sanofi; agennix ag
Customization	Available Upon Request

Key Segments Profiled in the PD1 Non-small Cell Lung Cancer Treatment Market Industry survey

By Drug Type:

• Nivolumab
• Pembrolizumab
• Atezolizumab
• Avelumab
• Durvalumab

By Cancer Type:

• Squamous Cell carcinoma
• Adenocarcinoma
• Large-cell carcinoma

By Treatment:

• Chemotherapy
• Targeted therapy
• Immunotherapy
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Frequently Asked Questions

What was the Historical Size of the Market?

The market witnessed a CAGR of 5.7% from 2018 to 2022.

What is the Expected Value of the Market?

The market is expected to reach USD 31.7 billion through 2033.

What is the Growth Outlook for Hospital Pharmacies?

The hospital pharmacies segment is estimated to register a growth rate of 12% until 2033.

What is North America's Growth Outlook?

North America’s market is expected to dominate with a market share of 42%.

What is the Present Market Value in 2023?

The market is valued at USD 26.96 billion in 2023.